APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Vector Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Recombinant Vector Vaccines Industry Growth and Trends Forecast to 2032

22 December 2025100 pages

Choose your research edition.

Industry ResearchRecombinant Vector Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Vector Vaccines Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Recombinant Vector Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Vector Vaccines Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Vector Vaccines Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Recombinant Vector Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., CNBG, SINOVAC BIOTECH, Zhifei, GSK, Hualan Bio, ChengDa Bio, NuoCheng Bio and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Recombinant Vector Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Recombinant Vector Vaccines market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Recombinant Vector Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Recombinant Vector Vaccines.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Recombinant Vector Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Recombinant Vector Vaccines Market by Company

SANOFI PASTEUR S.A.

CNBG

SINOVAC BIOTECH

Zhifei

GSK

Hualan Bio

ChengDa Bio

NuoCheng Bio

Novartis

Kangtai

Changsheng Life

Recombinant Vector Vaccines Segment by Type

Varicella

Influenza

Hepatitis

Pneumococcal

Pertussis, Diphtheria, tetanus

Others

Recombinant Vector Vaccines Segment by Application

For Adult

For Child

Recombinant Vector Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vector Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Recombinant Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Varicella Table 2. Major Company of Influenza Table 3. Major Company of Hepatitis Table 4. Major Company of Pneumococcal Table 5. Major Company of Pertussis, Diphtheria, tetanus Table 6. Major Company of Others Table 7. Global Recombinant Vector Vaccines Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Recombinant Vector Vaccines Sales by Type (2021-2026) & (k units) Table 9. Global Recombinant Vector Vaccines Sales Market Share in Volume by Type (2021-2026) Table 10. Global Recombinant Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 11. Global Recombinant Vector Vaccines Sales Market Share in Value by Type (2021-2026) Table 12. Global Recombinant Vector Vaccines Price by Type (2021-2026) & (US$/unit) Table 13. Global Recombinant Vector Vaccines Sales by Type (2027-2032) & (k units) Table 14. Global Recombinant Vector Vaccines Sales Market Share in Volume by Type (2027-2032) Table 15. Global Recombinant Vector Vaccines Sales by Type (2027-2032) & (US$ Million) Table 16. Global Recombinant Vector Vaccines Sales Market Share in Value by Type (2027-2032) Table 17. Global Recombinant Vector Vaccines Price by Type (2027-2032) & (US$/unit) Table 18. North America Recombinant Vector Vaccines Sales by Type (2021-2026) & (k units) Table 19. North America Recombinant Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Recombinant Vector Vaccines Sales by Type (2021-2026) & (k units) Table 21. Europe Recombinant Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Recombinant Vector Vaccines Sales by Type (2021-2026) & (k units) Table 23. Asia-Pacific Recombinant Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Recombinant Vector Vaccines Sales by Type (2021-2026) & (k units) Table 25. Latin America Recombinant Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Recombinant Vector Vaccines Sales by Type (2021-2026) & (k units) Table 27. Middle East and Africa Recombinant Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 28. Recombinant Vector Vaccines Industry Trends Table 29. Recombinant Vector Vaccines Industry Drivers Table 30. Recombinant Vector Vaccines Industry Opportunities and Challenges Table 31. Recombinant Vector Vaccines Industry Restraints Table 32. Global Recombinant Vector Vaccines Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Recombinant Vector Vaccines Revenue Market Share by Company (2021-2026) Table 34. Global Recombinant Vector Vaccines Sales by Company (2021-2026) & (k units) Table 35. Global Recombinant Vector Vaccines Sales Share by Company (2021-2026) Table 36. Global Recombinant Vector Vaccines Market Price by Company (2021-2026) & (US$/unit) Table 37. Global Recombinant Vector Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Recombinant Vector Vaccines Major Company Production Sites and Headquarters Table 39. Global Recombinant Vector Vaccines Company, Product Type & Application Table 40. Global Recombinant Vector Vaccines Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Recombinant Vector Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Recombinant Vector Vaccines Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Recombinant Vector Vaccines Sales by Region (2021-2026) & (k units) Table 45. Global Recombinant Vector Vaccines Sales Market Share in Volume by Region (2021-2026) Table 46. Global Recombinant Vector Vaccines Sales by Region (2021-2026) & (US$ Million) Table 47. Global Recombinant Vector Vaccines Sales Market Share in Value by Region (2021-2026) Table 48. Global Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 49. Global Recombinant Vector Vaccines Sales by Region (2027-2032) & (k units) Table 50. Global Recombinant Vector Vaccines Sales Market Share in Volume by Region (2027-2032) Table 51. Global Recombinant Vector Vaccines Sales by Region (2027-2032) & (US$ Million) Table 52. Global Recombinant Vector Vaccines Sales Market Share in Value by Region (2027-2032) Table 53. Global Recombinant Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 54. Global Recombinant Vector Vaccines Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Recombinant Vector Vaccines Sales by Application (2021-2026) & (k units) Table 56. Global Recombinant Vector Vaccines Sales Market Share in Volume by Application (2021-2026) Table 57. Global Recombinant Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 58. Global Recombinant Vector Vaccines Sales Market Share in Value by Application (2021-2026) Table 59. Global Recombinant Vector Vaccines Price by Application (2021-2026) & (US$/unit) Table 60. Global Recombinant Vector Vaccines Sales by Application (2027-2032) & (k units) Table 61. Global Recombinant Vector Vaccines Sales Market Share in Volume by Application (2027-2032) Table 62. Global Recombinant Vector Vaccines Sales by Application (2027-2032) & (US$ Million) Table 63. Global Recombinant Vector Vaccines Sales Market Share in Value by Application (2027-2032) Table 64. Global Recombinant Vector Vaccines Price by Application (2027-2032) & (US$/unit) Table 65. North America Recombinant Vector Vaccines Sales by Application (2021-2026) & (k units) Table 66. North America Recombinant Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Recombinant Vector Vaccines Sales by Application (2021-2026) & (k units) Table 68. Europe Recombinant Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Recombinant Vector Vaccines Sales by Application (2021-2026) & (k units) Table 70. Asia-Pacific Recombinant Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Recombinant Vector Vaccines Sales by Application (2021-2026) & (k units) Table 72. Latin America Recombinant Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Recombinant Vector Vaccines Sales by Application (2021-2026) & (k units) Table 74. Middle East and Africa Recombinant Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 75. SANOFI PASTEUR S.A. Company Information Table 76. SANOFI PASTEUR S.A. Business Overview Table 77. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio Table 79. SANOFI PASTEUR S.A. Recent Development Table 80. CNBG Company Information Table 81. CNBG Business Overview Table 82. CNBG Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. CNBG Recombinant Vector Vaccines Product Portfolio Table 84. CNBG Recent Development Table 85. SINOVAC BIOTECH Company Information Table 86. SINOVAC BIOTECH Business Overview Table 87. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio Table 89. SINOVAC BIOTECH Recent Development Table 90. Zhifei Company Information Table 91. Zhifei Business Overview Table 92. Zhifei Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Zhifei Recombinant Vector Vaccines Product Portfolio Table 94. Zhifei Recent Development Table 95. GSK Company Information Table 96. GSK Business Overview Table 97. GSK Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. GSK Recombinant Vector Vaccines Product Portfolio Table 99. GSK Recent Development Table 100. Hualan Bio Company Information Table 101. Hualan Bio Business Overview Table 102. Hualan Bio Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Hualan Bio Recombinant Vector Vaccines Product Portfolio Table 104. Hualan Bio Recent Development Table 105. ChengDa Bio Company Information Table 106. ChengDa Bio Business Overview Table 107. ChengDa Bio Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. ChengDa Bio Recombinant Vector Vaccines Product Portfolio Table 109. ChengDa Bio Recent Development Table 110. NuoCheng Bio Company Information Table 111. NuoCheng Bio Business Overview Table 112. NuoCheng Bio Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. NuoCheng Bio Recombinant Vector Vaccines Product Portfolio Table 114. NuoCheng Bio Recent Development Table 115. Novartis Company Information Table 116. Novartis Business Overview Table 117. Novartis Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Novartis Recombinant Vector Vaccines Product Portfolio Table 119. Novartis Recent Development Table 120. Kangtai Company Information Table 121. Kangtai Business Overview Table 122. Kangtai Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Kangtai Recombinant Vector Vaccines Product Portfolio Table 124. Kangtai Recent Development Table 125. Changsheng Life Company Information Table 126. Changsheng Life Business Overview Table 127. Changsheng Life Recombinant Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Changsheng Life Recombinant Vector Vaccines Product Portfolio Table 129. Changsheng Life Recent Development Table 130. North America Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 131. North America Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 132. North America Recombinant Vector Vaccines Sales Market Share by Country (2021-2026) Table 133. North America Recombinant Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 134. North America Recombinant Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 135. North America Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 136. North America Recombinant Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 137. North America Recombinant Vector Vaccines Market Share by Country (2021-2026) Table 138. North America Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 139. North America Recombinant Vector Vaccines Market Share Forecast by Country (2027-2032) Table 140. Europe Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 141. Europe Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 142. Europe Recombinant Vector Vaccines Sales Market Share by Country (2021-2026) Table 143. Europe Recombinant Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 144. Europe Recombinant Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 145. Europe Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 146. Europe Recombinant Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 147. Europe Recombinant Vector Vaccines Market Share by Country (2021-2026) Table 148. Europe Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 149. Europe Recombinant Vector Vaccines Market Share Forecast by Country (2027-2032) Table 150. Asia-Pacific Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 151. Asia-Pacific Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 152. Asia-Pacific Recombinant Vector Vaccines Sales Market Share by Country (2021-2026) Table 153. Asia-Pacific Recombinant Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 154. Asia-Pacific Recombinant Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 155. Asia-Pacific Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 156. Asia-Pacific Recombinant Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 157. Asia-Pacific Recombinant Vector Vaccines Market Share by Country (2021-2026) Table 158. Asia-Pacific Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 159. Asia-Pacific Recombinant Vector Vaccines Market Share Forecast by Country (2027-2032) Table 160. Latin America Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 161. Latin America Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 162. Latin America Recombinant Vector Vaccines Sales Market Share by Country (2021-2026) Table 163. Latin America Recombinant Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 164. Latin America Recombinant Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 165. Latin America Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 166. Latin America Recombinant Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 167. Latin America Recombinant Vector Vaccines Market Share by Country (2021-2026) Table 168. Latin America Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 169. Latin America Recombinant Vector Vaccines Market Share Forecast by Country (2027-2032) Table 170. Middle East and Africa Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 171. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 172. Middle East and Africa Recombinant Vector Vaccines Sales Market Share by Country (2021-2026) Table 173. Middle East and Africa Recombinant Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 174. Middle East and Africa Recombinant Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 175. Middle East and Africa Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. Middle East and Africa Recombinant Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 177. Middle East and Africa Recombinant Vector Vaccines Market Share by Country (2021-2026) Table 178. Middle East and Africa Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. Middle East and Africa Recombinant Vector Vaccines Market Share Forecast by Country (2027-2032) Table 180. Key Raw Materials Table 181. Raw Materials Key Suppliers Table 182. Recombinant Vector Vaccines Distributors List Table 183. Recombinant Vector Vaccines Customers List Table 184. Research Programs/Design for This Report Table 185. Authors List of This Report Table 186. Secondary Sources Table 187. Primary Sources List of Figures Figure 1. Recombinant Vector Vaccines Image Figure 2. Global Recombinant Vector Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Vector Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Vector Vaccines Sales (2021-2032) & (k units) Figure 5. Varicella Image Figure 6. Global Varicella Sales YoY Growth (2021-2032) & (k units) Figure 7. Influenza Image Figure 8. Global Influenza Sales YoY Growth (2021-2032) & (k units) Figure 9. Hepatitis Image Figure 10. Global Hepatitis Sales YoY Growth (2021-2032) & (k units) Figure 11. Pneumococcal Image Figure 12. Global Pneumococcal Sales YoY Growth (2021-2032) & (k units) Figure 13. Pertussis, Diphtheria, tetanus Image Figure 14. Global Pertussis, Diphtheria, tetanus Sales YoY Growth (2021-2032) & (k units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 17. Global Recombinant Vector Vaccines Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Recombinant Vector Vaccines Market Share by Type 2025 VS 2032 Figure 19. North America Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 20. North America Recombinant Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 21. Europe Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 22. Europe Recombinant Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 25. Latin America Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Recombinant Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Recombinant Vector Vaccines Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. For Adult Image Figure 32. Global For Adult Sales YoY Growth (2021-2032) & (k units) Figure 33. For Child Image Figure 34. Global For Child Sales YoY Growth (2021-2032) & (k units) Figure 35. Global Recombinant Vector Vaccines Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Recombinant Vector Vaccines Market Share by Application 2025 VS 2032 Figure 37. North America Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 38. North America Recombinant Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 39. Europe Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 40. Europe Recombinant Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 43. Latin America Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Recombinant Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 47. North America Recombinant Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. North America Recombinant Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Recombinant Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Recombinant Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Europe Recombinant Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Recombinant Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Recombinant Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Asia-Pacific Recombinant Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Recombinant Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Recombinant Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Latin America Recombinant Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Recombinant Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Recombinant Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Middle East and Africa Recombinant Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Recombinant Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Recombinant Vector Vaccines Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Recombinant Vector Vaccines Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Varicella
  • Influenza
  • Hepatitis
  • Pneumococcal
  • Pertussis, Diphtheria, tetanus
  • Others
Applications
  • For Adult
  • For Child
Companies covered
  • SANOFI PASTEUR S.A.
  • CNBG
  • SINOVAC BIOTECH
  • Zhifei
  • GSK
  • Hualan Bio
  • ChengDa Bio
  • NuoCheng Bio
  • Novartis
  • Kangtai
  • Changsheng Life

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Vector Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Recombinant Vector Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Recombinant Vector Vaccines Market by Type
  6. 1.3.1 Varicella
  7. 1.3.2 Influenza
  8. 1.3.3 Hepatitis
  9. 1.3.4 Pneumococcal
  10. 1.3.5 Pertussis, Diphtheria, tetanus
  11. 1.3.6 Others
  12. 1.4 Global Recombinant Vector Vaccines Market Size by Type
  13. 1.4.1 Global Recombinant Vector Vaccines Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Recombinant Vector Vaccines Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Recombinant Vector Vaccines Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Recombinant Vector Vaccines Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Recombinant Vector Vaccines Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Recombinant Vector Vaccines Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Recombinant Vector Vaccines Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Recombinant Vector Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Recombinant Vector Vaccines Industry Trends
  2. 2.2 Recombinant Vector Vaccines Industry Drivers
  3. 2.3 Recombinant Vector Vaccines Industry Opportunities and Challenges
  4. 2.4 Recombinant Vector Vaccines Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Recombinant Vector Vaccines Revenue (2021-2026)
  2. 3.2 Global Top Players by Recombinant Vector Vaccines Sales (2021-2026)
  3. 3.3 Global Top Players by Recombinant Vector Vaccines Price (2021-2026)
  4. 3.4 Global Recombinant Vector Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Vector Vaccines Major Company Production Sites & Headquarters
  6. 3.6 Global Recombinant Vector Vaccines Company, Product Type & Application
  7. 3.7 Global Recombinant Vector Vaccines Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Vector Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Vector Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Vector Vaccines Tier 1, Tier 2, and Tier 3
4 Recombinant Vector Vaccines Regional Status and Outlook
  1. 4.1 Global Recombinant Vector Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Recombinant Vector Vaccines Historic Market Size by Region
  3. 4.2.1 Global Recombinant Vector Vaccines Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Recombinant Vector Vaccines Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Recombinant Vector Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Recombinant Vector Vaccines Forecasted Market Size by Region
  7. 4.3.1 Global Recombinant Vector Vaccines Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Recombinant Vector Vaccines Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Recombinant Vector Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Recombinant Vector Vaccines by Application
  1. 5.1 Recombinant Vector Vaccines Market by Application
  2. 5.1.1 For Adult
  3. 5.1.2 For Child
  4. 5.2 Global Recombinant Vector Vaccines Market Size by Application
  5. 5.2.1 Global Recombinant Vector Vaccines Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Recombinant Vector Vaccines Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Recombinant Vector Vaccines Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Recombinant Vector Vaccines Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Recombinant Vector Vaccines Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Recombinant Vector Vaccines Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Recombinant Vector Vaccines Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Recombinant Vector Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 SANOFI PASTEUR S.A.
  2. 6.1.1 SANOFI PASTEUR S.A. Company Information
  3. 6.1.2 SANOFI PASTEUR S.A. Business Overview
  4. 6.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
  6. 6.1.5 SANOFI PASTEUR S.A. Recent Developments
  7. 6.2 CNBG
  8. 6.2.1 CNBG Company Information
  9. 6.2.2 CNBG Business Overview
  10. 6.2.3 CNBG Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 CNBG Recombinant Vector Vaccines Product Portfolio
  12. 6.2.5 CNBG Recent Developments
  13. 6.3 SINOVAC BIOTECH
  14. 6.3.1 SINOVAC BIOTECH Company Information
  15. 6.3.2 SINOVAC BIOTECH Business Overview
  16. 6.3.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
  18. 6.3.5 SINOVAC BIOTECH Recent Developments
  19. 6.4 Zhifei
  20. 6.4.1 Zhifei Company Information
  21. 6.4.2 Zhifei Business Overview
  22. 6.4.3 Zhifei Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
  24. 6.4.5 Zhifei Recent Developments
  25. 6.5 GSK
  26. 6.5.1 GSK Company Information
  27. 6.5.2 GSK Business Overview
  28. 6.5.3 GSK Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 GSK Recombinant Vector Vaccines Product Portfolio
  30. 6.5.5 GSK Recent Developments
  31. 6.6 Hualan Bio
  32. 6.6.1 Hualan Bio Company Information
  33. 6.6.2 Hualan Bio Business Overview
  34. 6.6.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
  36. 6.6.5 Hualan Bio Recent Developments
  37. 6.7 ChengDa Bio
  38. 6.7.1 ChengDa Bio Company Information
  39. 6.7.2 ChengDa Bio Business Overview
  40. 6.7.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
  42. 6.7.5 ChengDa Bio Recent Developments
  43. 6.8 NuoCheng Bio
  44. 6.8.1 NuoCheng Bio Company Information
  45. 6.8.2 NuoCheng Bio Business Overview
  46. 6.8.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
  48. 6.8.5 NuoCheng Bio Recent Developments
  49. 6.9 Novartis
  50. 6.9.1 Novartis Company Information
  51. 6.9.2 Novartis Business Overview
  52. 6.9.3 Novartis Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Novartis Recombinant Vector Vaccines Product Portfolio
  54. 6.9.5 Novartis Recent Developments
  55. 6.10 Kangtai
  56. 6.10.1 Kangtai Company Information
  57. 6.10.2 Kangtai Business Overview
  58. 6.10.3 Kangtai Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Kangtai Recombinant Vector Vaccines Product Portfolio
  60. 6.10.5 Kangtai Recent Developments
  61. 6.11 Changsheng Life
  62. 6.11.1 Changsheng Life Company Information
  63. 6.11.2 Changsheng Life Business Overview
  64. 6.11.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
  66. 6.11.5 Changsheng Life Recent Developments
7 North America by Country
  1. 7.1 North America Recombinant Vector Vaccines Sales by Country
  2. 7.1.1 North America Recombinant Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Recombinant Vector Vaccines Sales by Country (2021-2026)
  4. 7.1.3 North America Recombinant Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 7.2 North America Recombinant Vector Vaccines Market Size by Country
  6. 7.2.1 North America Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Recombinant Vector Vaccines Market Size by Country (2021-2026)
  8. 7.2.3 North America Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Recombinant Vector Vaccines Sales by Country
  2. 8.1.1 Europe Recombinant Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Recombinant Vector Vaccines Sales by Country (2021-2026)
  4. 8.1.3 Europe Recombinant Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Recombinant Vector Vaccines Market Size by Country
  6. 8.2.1 Europe Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Recombinant Vector Vaccines Market Size by Country (2021-2026)
  8. 8.2.3 Europe Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Recombinant Vector Vaccines Sales by Country
  2. 9.1.1 Asia-Pacific Recombinant Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Recombinant Vector Vaccines Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Recombinant Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Recombinant Vector Vaccines Market Size by Country
  6. 9.2.1 Asia-Pacific Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Recombinant Vector Vaccines Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Recombinant Vector Vaccines Sales by Country
  2. 10.1.1 South America Recombinant Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Recombinant Vector Vaccines Sales by Country (2021-2026)
  4. 10.1.3 South America Recombinant Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 10.2 South America Recombinant Vector Vaccines Market Size by Country
  6. 10.2.1 South America Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Recombinant Vector Vaccines Market Size by Country (2021-2026)
  8. 10.2.3 South America Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Recombinant Vector Vaccines Sales by Country
  2. 11.1.1 Middle East and Africa Recombinant Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Recombinant Vector Vaccines Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Recombinant Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Recombinant Vector Vaccines Market Size by Country
  6. 11.2.1 Middle East and Africa Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Recombinant Vector Vaccines Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Recombinant Vector Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Recombinant Vector Vaccines Value Chain Analysis
  2. 12.1.1 Recombinant Vector Vaccines Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Recombinant Vector Vaccines Production Mode & Process
  7. 12.2 Recombinant Vector Vaccines Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Recombinant Vector Vaccines Distributors
  10. 12.2.3 Recombinant Vector Vaccines Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst